Xencor Inc. | Mutual Funds
Mutual Funds that own Xencor Inc.
PRIMECAP Odyssey Aggressive Growth Fund
5,091,182
9.11%
399,400
1.89%
06/30/2018
T Rowe Price Health Sciences Fund
1,616,942
2.9%
42,923
0.53%
06/30/2018
Fidelity Select Biotechnology Portfolio
1,543,843
2.77%
0
0.7%
07/31/2018
Vanguard Investment Series Plc - US Opportunities Fund
1,473,025
2.64%
18,000
1.95%
06/30/2018
T Rowe Price New Horizons Fund
1,402,532
2.5%
38,411
0.24%
06/30/2018
Fidelity Growth Company Fund
1,262,143
2.25%
-6,848
0.11%
07/31/2018
Vanguard Total Stock Market Index Fund
1,196,287
2.14%
828
0.01%
07/31/2018
Fidelity Select Health Care Portfolio
1,053,412
1.89%
0
0.57%
07/31/2018
PRIMECAP Odyssey Growth Fund
992,700
1.78%
992,700
0.31%
06/30/2018
iShares Russell 2000 ETF
967,349
1.73%
-516
0.08%
09/06/2018
| Address |
111 West Lemon Avenue
Monrovia California 91016
United States
|
|
Employees
|
- |
| Website |
http://www.xencor.com |
| Updated |
07/08/2019 |
| Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. |
